Consultant Oncologist
Stephen Falk qualified from Liverpool University in 1983 and spent a period in Liverpool undertaking a general medical rotation. He then trained in oncology in Cardiff and Cambridge, becoming a Consultant in Bristol in 1994.
His major clinical interest is gastro-intestinal cancer (esophagus, stomach, pancreas, and colorectal). A further interest in lung cancer and clinical research was stimulated as an MRC Clinical Scientist in Norman Bleehens' unit in Cambridge where the MRC Cancer Trials Unit was situated at the time. An MD related to lung cancer and scheduling of topoisomerase poisons with and without radiation is the basis of on-going interest in chemo-radiation interactions.
Stephen retired from both NHS and private practice on July 31, 2025, after more than 31 years as a consultant.
Previously he had a challenging clinical load seeing up to 1,000 new patients with cancer annually. Until 2018, he was Clinical Director of the West of England Clinical Research Network, whose job is to fund the NHS costs of delivering research activity in the NHS, and chaired the NCRI research Pancreatic Sub Group until 2018.
Stephen has provided oncology advice to Scottish Widows/HBOS from 2008 and more recently has started assisting RGA.